Price Alert

Nuvation Bio Inc. (NUVB)

NYSE: NUVB · Real-Time Price · USD

2.75

-0.01 (-0.36%)

At close: Aug 15, 2025, 12:50 PM

-0.36% (1D)

Bid	2.75
Market Cap	942.96M
Revenue (ttm)	14.36M
Net Income (ttm)	-202.9M
EPS (ttm)	-0.38
PE Ratio (ttm)	-7.25
Forward PE	-3.89
Analyst	Buy

Ask	2.76
Volume	2,526,966
Avg. Volume (20D)	6,300,695
Open	2.77
Previous Close	2.76
Day's Range	2.73 - 2.87
52-Week Range	1.54 - 3.46
Beta	1.35

About NUVB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol NUVB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for NUVB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Nuvation Bio has released their quartely earnings on Aug 7, 2025:

Revenue of $4.83M exceeds estimates by $3.58M, with 236.79% YoY growth.

EPS of -0.17 misses estimates by -0.02, with -13.33% YoY decline.

Next Earnings Release

Nuvation Bio Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

7 months ago

+14.44%

Nuvation Bio shares are trading higher after RBC C... Unlock content with Pro Subscription

News

1 week ago · zacks.com

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.

1 week ago · businesswire.com

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today reported financial results for the second quart...

3 weeks ago · businesswire.com

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference ...

1 month ago · zacks.com

All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy

Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · businesswire.com

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

2 months ago · reuters.com

US FDA approves Nuvation Bio's lung cancer therapy

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of lung cancer.

2 months ago · businesswire.com

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

2 months ago · https://www.defenseworld.net

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $925,000 Holdings in Nuvation Bio Inc. (NYSE:NUVB)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Nuvation Bio Inc. (NYSE:NUVB – Free Report) by 54.2% in the 4th quarter, according to the company in i...

2 months ago · businesswire.com

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting